These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26640977)

  • 1. Moving forward in uveitis therapy: preclinical to phase II clinical trial drug development.
    Salazar-Méndez R; Yilmaz T; Cordero-Coma M
    Expert Opin Investig Drugs; 2016; 25(2):195-214. PubMed ID: 26640977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs for the treatment of uveitis.
    Leung TG; Thorne JE
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):513-21. PubMed ID: 24274613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Patents and Emerging Therapeutics on Ocular Inflammation and Allergy.
    Agrahari V; Aulgur Z; Thukral S; Dhall N; Conley R; Mitra AK
    Recent Pat Inflamm Allergy Drug Discov; 2017; 11(2):92-106. PubMed ID: 28901856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II.
    Lee K; Bajwa A; Freitas-Neto CA; Metzinger JL; Wentworth BA; Foster CS
    Expert Opin Biol Ther; 2014 Nov; 14(11):1651-66. PubMed ID: 25226284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials.
    Thng ZX; Bromeo AJ; Mohammadi SS; Khatri A; Tran ANT; Akhavanrezayat A; T T Than N; Nguyen KS; Yoo WS; Mobasserian A; Or CCM; Nguyen QD
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):297-309. PubMed ID: 38129984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological agents for the treatment of uveitis.
    Servat JJ; Mears KA; Black EH; Huang JJ
    Expert Opin Biol Ther; 2012 Mar; 12(3):311-28. PubMed ID: 22339439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Road to remission: a comprehensive review of therapy in uveitis.
    Siddique SS; Shah R; Suelves AM; Foster CS
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1497-515. PubMed ID: 21936708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF inhibition for ophthalmic indications: current status and outlook.
    Rifkin LM; Birnbaum AD; Goldstein DA
    BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues.
    Cordero-Coma M; Salazar-Méndez R; Yilmaz T
    Expert Opin Drug Saf; 2015 Jul; 14(7):1071-86. PubMed ID: 25950807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues.
    Cordero-Coma M; Salazar-Méndez R; Yilmaz T
    Expert Opin Drug Saf; 2015; 14(9):1353-71. PubMed ID: 26118392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced uveitis.
    Cordero-Coma M; Salazar-Méndez R; Garzo-García I; Yilmaz T
    Expert Opin Drug Saf; 2015 Jan; 14(1):111-26. PubMed ID: 25323655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding uveitis: the impact of research on visual outcomes.
    de Smet MD; Taylor SR; Bodaghi B; Miserocchi E; Murray PI; Pleyer U; Zierhut M; Barisani-Asenbauer T; LeHoang P; Lightman S
    Prog Retin Eye Res; 2011 Nov; 30(6):452-70. PubMed ID: 21807112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of systemic therapy for noninfectious uveitis.
    Ormaechea MS; Hassan M; Onghanseng N; Park JH; Mahajan S; Al-Kirwi KY; Uludag G; Halim MS; Schlaen A; Sepah YJ; Do DV; Nguyen QD
    Expert Opin Drug Saf; 2019 Dec; 18(12):1219-1235. PubMed ID: 31801415
    [No Abstract]   [Full Text] [Related]  

  • 17. Small molecules as therapy for uveitis: a selected perspective of new and developing agents.
    Pleyer U; Algharably EA; Feist E; Kreutz R
    Expert Opin Pharmacother; 2017 Sep; 18(13):1311-1323. PubMed ID: 28750572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone for ocular inflammation.
    Saraiya NV; Goldstein DA
    Expert Opin Pharmacother; 2011 May; 12(7):1127-31. PubMed ID: 21457057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies in Development for Non-Infectious Uveitis.
    Sadiq MA; Agarwal A; Hassan M; Afridi R; Sarwar S; Soliman MK; Do DV; Nguyen QD
    Curr Mol Med; 2015; 15(6):565-77. PubMed ID: 26238367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.